Daniel P. Amos - Chairman and Chief Executive Officer
Analyst · Morgan Stanley
Good morning and thank you for joining us today. Overall, I am pleased with the way we started 2008. Although we just have one quarter under our belt, I believe we are well positioned to achieve our objective of operating earnings per share growth this year. Let me give you more detail about the quarter beginning with Aflac Japan As a leading contributor to our consolidated financial statements, we were very satisfied with Aflac Japan's operating and financial results in the first quarter of 2008. In addition, our top line was consistent with our budget for the year and the benefit ratio continued to improve as we expected. As a result, we again produced solid pre-tax earnings growth. I was especially pleased with Aflac Japan's continued sales improvement. I hope you remember that when we released the fourth quarter earnings, we said that Aflac Japan's sales would start slow in 2008. Personally, I thought the first quarter sales could be flat. That was largely because we knew it would take time to build momentum in the bank channels. In fact only 1% of sales came from the banks in the quarter. Yet despite our caution, we began the year with very good quarter. Total new annualized sales rose 5% to 27.6 billion yen. That result, is much better than we had anticipated and in line with our annual sales objective. With bank sales still in the infancy, we believe our solid first quarter sales benefited instead from recent product introductions. Medical sales improved sharply in the quarter, rising 17.6% over a year ago. Medical sales were helped by Gentle EVER, our non-standard medical product, which targets consumers aged 40 and older, who typically would not qualify for our standard EVER product. During the quarter, we sold 12,400 Gentle EVER policies. Gentle EVER sales of 1.4 billion yen accounted for approximately 15% of the medical sales in the quarter. Since we began marketing Gentle EVER last August, it became the number one selling non-standard product in Japan. We were also pleased with cancer insurance sales, up 2.8%. We expected to see solid cancer sales this year in par because of the favorable reception of our new Cancer Forte product. This product is the first major revision to our cancer policy in more than six years. Cancer Forte increases daily out-patient benefits, adds an annuity for newly diagnosed patients and offers the canceling and doctor referral benefit. On March 24th, Dai-ichi Mutual Life joined Aflac Japan in selling Cancer Forte. Earlier in the year we introduced the special cancer policy that allows existing policy holders to upgrade their coverage to that of the Cancer Forte. In the first quarter, we sold approximately 54,500 of these upgrade policies. We believe this will be an effective means for enhancing customers' coverage, while also leveraging our policy holder base to increase sales. We also believe sales of cancer medical insurance will benefit from the addition of our new sales channels. As we discussed, we expect to leverage our long standing and extensive relationships in the banking sector to secure a significant number of selling agreement once the banks could finally offer their products to the... over the counter. That is exactly what has happened. At the end of March, we had agreements with 55 banks to sell our products. That number rose to 90 on April, the 1st, and by mid-year, we expect that number of agreements to be about 150 bank distributors. One reason we expect the numbers to increase is endorsement of Aflac's products by the National Association of Shinkin Banks. This association of about 280 Shinkin banks chose Aflac as one of only four companies to provide third sector products. Not only was Aflac the only foreign company chosen but Aflac was the only company selected to sell both cancer and medical insurance. Even tough we don't know with certainty how much business the bank channels would generate, we believe this new channel will gain momentum as the year progresses. We look for significantly better bank channel sales in the second quarter and this new channel should give us greater confidence in achieving our sales adjective for the year. We are also very excited about the opportunity to sell Cancer Forte through an agreement with Japan Post network. As I am sure you are aware, Japan Post chose Aflac as the cancer insurance provider through their network company. Initially we expect to sell through about 300 postal outlets, beginning on October, the 1st of this year. Needless to say, we believe this is a great opportunity for both Japan Post and Aflac. We also believe we are benefiting from the training initiatives. New agents who have gone through the new associate basic training program have generated better production than those who started before the training program was implemented. Although recruiting has been more challenging due to the tighter labor market in Japan, we are still focused on expanding our traditional distribution channel. In that regard, we recruited 771 new associates or agencies in the first quarter, which was 14.9% higher than a year ago. Remember that we are also adding significant number of licensed agents this year through the bank channel. I firmly believe there is a strong need for our products in Japan and I think we are well positioned to achieve our sales objective of a 3% to 7% increase for the year. We believe that's a reasonable target and we expect to produce strong financial results that are consistent with our budget for 2008. Now let me turn to the business in the United States. We are pleased with Aflac U.S. for financial performance in the first quarter. Our top line was consistent, with our expectations and our pre-tax earnings were better than our target. Total new annualized premium sales were 0.4% to 353 million. We were not surprised that sales were sluggish. However, we did think that sales would be up about 3%. You will recall that in the fourth quarter press release, we expected first quarter sales to be weak. There were a couple of reasons behind I think. First, we pointed out that we have transferred $8 million of sales for the first quarter of this year to the fourth quarter of last year due to administrative changes that we had in processing conversions. Second, we also needed our agents, particularly our veteran agents pushed very hard at the end of 2007, and as result, sales were sharply down in January. In addition, we had one less production day in the first quarter compared with the year ago. I'd like to point out that sales improved after the weak start of the year. From the beginning of February to the end of last week, our sales were up 6.5%. The number of average weekly producer rose 0.2% in the first quarter. However, the number of new average weekly producers, are those who in their first year increased 2.7% in the quarter. Production of new associates rose 4.2% over last year, and in addition we were pleased with the growth of our new payroll deduction accounts, which was up 8.5% over last year. That leads us to believe that the fundamental approach to building an effective distribution is still working and we continue to focus on that. As we've said previously, we've been in weak economies. We have found it easier to recruit because of rising unemployment means salary jobs are more difficult to come by. We think the weaker U.S. economy resulted in good recruiting increase for the quarter. Recruiting was up 8.6% in the first quarter, so almost 6500 new associates. I know many of you have asked whether the U.S. economy is affecting other aspects of our business. As we've said before, we really have not experienced any material impact on claims or sales in fast economic downturns. The last recession occurred in 2001, when our sales were up 29%. That incredible sales growth was attributable to the success of the new Aflac duck advertising campaign, which could have simply mitigated any impact of the recession. Of course, we recognize that the current economy is impacting consumers and we are seeing lower penetration rates in accounts compared to last year. However, we are sure of one thing, the need for our products we sell have not changed. The incidence of cancer, accident and other serious health events does not fluctuate during economic cycles. In fact, I believe the need for our products is actually more compelling when the economy weakens because of the financial risk to the household, becomes more pronounced. With the price of food and gas climbing so rapidly, coping with those rising costs is even more burdensome to the health event occurs. That's precisely why our products provide distinct value to the average American households. We are taking steps to amplify that message to our sales force. This past Monday, we held a national training day that was offered to the entire sales force. One of the main objectives of this training day was to convey to the sales force, how a weak economy enhances a need for our products, and to train them how to better sell in this economy environment. Rest assured, we continue to take every opportunity we can to provide our sales force with the tools and skills that they need to be more successful. At the same time, there are other initiatives that we are working on, that we believe will help us tap into this fast U.S. market. At our analyst meeting next month, we'll talk about our new business-to-business marketing. This is the first time, we have directly approached business owners and we are excited about its potential. We have created business-to-business television commercials, which expect to begin running in May. These initial testings of these commercials was very high and we believe they will help us communicate our brand message to employers. We are also going to continue to segment the market to more effectively meet the needs of the specific consumers such as the Hispanic market. We will continue to enhance our distribution by looking more cautiously at the non-traditional channels such as national insurance brokers. I am pleased with the direction of our operation and enthusiastic about the opportunities we see in the marketplace. Our objective is still an 8% to 12% increase in sales for the full year and I expect our sales growth to improve, as I still believe our sales target is achievable, although it's obviously tougher than it was... than we had originally thought. I am counting on the marketing and sales officers as well as the field force to do what they can to help drive sales. I believe employers and workers alike are gaining a better understanding of our products and our services, and I am certain we have an effective combination of product, distribution, customer service and brand to meet customer needs. On a consolidated basis, I am pleased with the financial position. Our balance sheet is still marked by a conservative investment posture and very favorable risk profile. The credit ratings of our holdings remain high as you know and we do not have any direct investment exposure to sub-prime lending markets. We have limited investment exposure to CMOs asset-backed securities or CDOs, and all the investments in those areas are highly rated. We also have a very strong risk-based capital. Our RBC ratio for 2007 was 574. Although it declined some what from 2006, keep in mind that we transferred $1.4 billion to the parent company in 2007. That capital transfer allowed us to repurchase 12.5 million shares in February 2008. In other words, they impacted the funding of our 2008 share repurchase was reflected in 2007 RBC ratio. As I mentioned in our press release, we have narrowed our outlook for this year from a 13% to 15% increase in operating earnings on a diluted basis before the impact of currency to 14% to 15% increase. I have a high degree of confidence that we will achieve that target, and we hope to grow at the high end of that range this year. We are very pleased with our U.S. financial results, which were in line or better than expectations. At the same time, I am extremely pleased with Aflac Japan's continued recovery of new sales. Aflac Japan sales results exceeded our expectations for the quarter and as a contributor to more than 70% of the consolidated earnings, Aflac Japan's financial results were solid and consistent with our target. I am still focused on increasing operating earnings per share by at least 15% annually, excluding the impact of the Yen from my first 20 years as CEO. If attend our analyst meeting next month, you will hear about our 2009 earnings target. Beyond my first 20 years as CEO, I still think we can produce another ten years of double-digit earnings growth. As we look ahead, we believe our strong earnings growth will reflect our underlying earnings power of our insurance operations in Japan and the United States. It will also reflect our prudent approach to deploying excess capital in a way that benefits shareholders. Ken?